D. E. Shaw & Co., Inc. Novo Nordisk A S Transaction History

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 1,049,519 shares of NVO stock, worth $50.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,049,519

Previous 1,640,500 36.02%

Holding current value

$50.9 Million

Previous $113 Million 48.57%

% of portfolio

0.04%

Previous 0.09%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$45.38 - $71.7 $47.6 Million - $75.3 Million	1,049,519 New	1,049,519 $58.2 Million
Q1 2025 May 15, 2025	BUY	$69.3 - $90.95 $36.6 Million - $48 Million	527,584 Added 25.67%	2,582,572 $179 Million
Q4 2024 Feb 14, 2025	BUY	$85.0 - $120.04 $97.7 Million - $138 Million	1,149,403 Added 126.92%	2,054,988 $177 Million
Q3 2024 Nov 14, 2024	BUY	$119.07 - $145.42 $102 Million - $125 Million	858,885 Added 1839.15%	905,585 $108 Million
Q2 2024 Aug 14, 2024	SELL	$122.71 - $146.91 $11 Million - $13.2 Million	-89,973 Reduced 65.83%	46,700 $6.67 Million

Q1 2024 May 15, 2024	BUY	$102.11 - $135.92 $9.94 Million - $13.2 Million	97,376 Added 247.79%	136,673 $17.5 Million
Q4 2023 Feb 14, 2024	SELL	$87.78 - $105.45 $617,356 - $741,629	-7,033 Reduced 15.18%	39,297 $4.07 Million
Q3 2023 Nov 14, 2023	SELL	$90.94 - $199.54 $6.21 Million - $13.6 Million	-68,265 Reduced 59.57%	46,330 $4.21 Million
Q2 2023 Aug 14, 2023	BUY	$155.98 - $172.65 $15.9 Million - $17.6 Million	101,823 Added 797.24%	114,595 $18.5 Million
Q1 2023 May 15, 2023	SELL	$132.34 - $159.14 $65.8 Million - $79.2 Million	-497,526 Reduced 97.5%	12,772 $2.03 Million
Q4 2022 Feb 14, 2023	BUY	$102.55 - $135.33 $51.4 Million - $67.8 Million	500,902 Added 5331.01%	510,298 $69.1 Million
Q3 2022 Nov 14, 2022	SELL	$95.28 - $116.93 $21.4 Million - $26.3 Million	-224,572 Reduced 95.98%	9,396 $936,000
Q2 2022 Aug 15, 2022	BUY	$103.24 - $121.81 $23.9 Million - $28.2 Million	231,146 Added 8190.86%	233,968 $26.1 Million
Q1 2022 May 16, 2022	BUY	$93.1 - $112.54 $262,728 - $317,587	2,822 New	2,822 $313,000
Q4 2021 Feb 14, 2022	SELL	$95.88 - $117.08 $10.6 Million - $13 Million	-110,839 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$84.42 - $106.62 $2.35 Million - $2.97 Million	-27,860 Reduced 20.09%	110,839 $10.6 Million
Q2 2021 Aug 16, 2021	BUY	$67.66 - $84.76 $7 Million - $8.77 Million	103,432 Added 293.28%	138,699 $11.6 Million
Q1 2021 May 17, 2021	BUY	$67.06 - $75.82 $2.37 Million - $2.67 Million	35,267 New	35,267 $2.38 Million
Q3 2019 Nov 14, 2019	SELL	$47.54 - $53.43 $1.15 Million - $1.29 Million	-24,089 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$46.79 - $52.47 $1.61 Million - $1.81 Million	-34,479 Reduced 58.87%	24,089 $1.23 Million
Q1 2019 May 15, 2019	SELL	$46.36 - $52.63 $4.72 Million - $5.36 Million	-101,902 Reduced 63.5%	58,568 $3.06 Million
Q4 2018 Feb 14, 2019	SELL	$41.54 - $47.25 $312,505 - $355,461	-7,523 Reduced 4.48%	160,470 $7.39 Million
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $27.3 Million - $29.9 Million	-583,698 Reduced 77.65%	167,993 $7.92 Million
Q2 2018 Aug 14, 2018	BUY	$44.29 - $50.42 $33.3 Million - $37.9 Million	751,691 New	751,691 $34.7 Million
Q1 2018 May 15, 2018	SELL	$48.49 - $58.14 $1.5 Million - $1.8 Million	-30,921 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$47.53 - $53.73 $14.7 Million - $16.6 Million	-309,588 Reduced 90.92%	30,921 $1.66 Million
Q3 2017 Nov 14, 2017	BUY	$41.15 - $49.22 $14 Million - $16.8 Million	340,509	340,509 $16.4 Million

Others Institutions Holding NVO

# of Institutions

1,693

Shares Held

303M

Call Options Held

25.9M

Put Options Held

43.8M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $109B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account